

Olivier Mir

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5631442/olivier-mir-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97
papers

2,569
citations

25
h-index

49
g-index

105
ext. papers

3,334
ext. citations

7.4
avg, IF

4.67
L-index

#	Paper	IF	Citations
97	Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy - brachytherapy association.. <i>Oral Oncology</i> , 2022 , 125, 105715	4.4	1
96	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.. <i>Acta Oncologica</i> , 2022 , 1-6	3.2	0
95	Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents. <i>Cancers</i> , 2021 , 13,	6.6	5
94	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , 2021 , 145, 132-142	7.5	24
93	Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis-Response. <i>Clinical Cancer Research</i> , 2021 , 27, 2120	12.9	
92	Targeting the VEGF Pathway in Osteosarcoma. <i>Cells</i> , 2021 , 10,	7.9	3
91	Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. <i>Targeted Oncology</i> , 2021 , 16, 485-492	5	0
90	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021 , 150, 108-118	7.5	3
89	Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?. <i>Clinical and Translational Radiation Oncology</i> , 2021 , 29, 79-84	4.6	0
88	Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma. <i>Cancer Medicine</i> , 2021 , 10, 230-236	4.8	3
87	Nurse navigators' telemonitoring for cancer patients with COVID-19: a French case study. <i>Supportive Care in Cancer</i> , 2021 , 29, 4485-4492	3.9	3
86	The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2021 , 26, 389-396	5.7	3
85	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021 , 26, e639-e649	5.7	11
84	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. <i>Pharmacology & Therapeutics</i> , 2021 , 107986	13.9	2
83	Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. <i>JCO Oncology Practice</i> , 2021 , 17, e1311-e1317	2.3	0
82	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3128-3139	2.2	12
81	How to Design a Remote Patient Monitoring System? A French Case Study. <i>BMC Health Services Research</i> , 2020 , 20, 434	2.9	5

80	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. <i>European Journal of Cancer</i> , 2020 , 134, 62-74	7.5	21
79	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 935-946	21.7	101
78	Endometriosis. <i>New England Journal of Medicine</i> , 2020 , 383, 193-194	59.2	2
77	Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103029	7	11
76	A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 147, 102889	7	11
75	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. <i>European Journal of Cancer</i> , 2020 , 128, 119-128	7.5	25
74	Letter: Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era. <i>Neurosurgery</i> , 2020 , 86, E480-E482	3.2	2
73	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 446-455	21.7	92
72	Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?. <i>European Journal of Cancer</i> , 2020 , 128, 103-106	7.5	5
71	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. <i>European Journal of Cancer</i> , 2020 , 126, 45-55	7.5	5
70	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers. <i>European Journal of Cancer</i> , 2020 , 128, 107-118	7.5	16
69	Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of Mutational Status. <i>Clinical Cancer Research</i> , 2020 , 26, 6277-6283	12.9	4
68	Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. <i>Cancers</i> , 2020 , 12,	6.6	2
67	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
66	Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 141, 112-124	7	6
65	Basic Knowledge in Soft Tissue Sarcoma. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1255-1261	17	34
64	The impact of the Paris terrorist attacks on the mental health of resident physicians. <i>BMC Psychiatry</i> , 2019 , 19, 79	4.2	12
63	Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1479-1485	12.9	36

62	Clinical Activity of Sunitinib and Regorafenib in Endometriosis. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 2591-2693	2
61	A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. <i>Cancer Treatment Reviews</i> , 2019 , 72, 37-44	14.4 17
60	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 120-133	21.7 134
59	Everolimus induced mood changes in breast cancer patients: a case-control study. <i>Investigational New Drugs</i> , 2018 , 36, 503-508	4.3 5
58	Interventional radiology: Role in the treatment of sarcomas. <i>European Journal of Cancer</i> , 2018 , 94, 148-155	16
57	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018 , 99, 28-36	7.5 9
56	Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. <i>Investigational New Drugs</i> , 2018 , 36, 156-162	4.3 15
55	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018 , 23, 62-70	5.7 42
54	Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2018 , 103, 88-97	7.5 17
53	Patterns of care and outcomes of patients with METAstatic soft tissue SARcoma in a real-life setting: the METASARC observational study. <i>BMC Medicine</i> , 2017 , 15, 78	11.4 91
52	REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. <i>Cancer</i> , 2017 , 123, 2294-2302	6.4 30
51	PD-1 inhibition in bone sarcoma and soft-tissue sarcoma. <i>Lancet Oncology, The</i> , 2017 , 18, 1430-1431	21.7 4
50	Colchicine is an active treatment for everolimus-induced oral ulcers. <i>European Journal of Cancer</i> , 2017 , 87, 209-211	7.5 2
49	Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. <i>Investigational New Drugs</i> , 2017 , 35, 247-249	4.3 5
48	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. <i>Scientific Reports</i> , 2017 , 7, 17917	4.9 8
47	Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. <i>British Journal of Cancer</i> , 2017 , 117, 1787-1797	8.7 21
46	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1732-1742	21.7 141
45	Hepatitis B reactivation during everolimus treatment. <i>Acta Oncologica</i> , 2016 , 55, 1505-1506	3.2 4

44	Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). <i>Oncotarget</i> , 2016 , 7, 73984-73994	3.3	18
43	Pharmacokinetics of Systemic Anticancer Therapies During Pregnancy 2016 , 55-70		
42	Individualized Pazopanib Dosing-Letter. <i>Clinical Cancer Research</i> , 2016 , 22, 6298	12.9	2
41	Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 632-41	21.7	76
40	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. <i>European Journal of Cancer</i> , 2016 , 66, 75-82	7.5	2
39	Nilotinib versus imatinib for GIST. <i>Lancet Oncology, The</i> , 2015 , 16, e311	21.7	1
38	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2797-802	2.2	117
37	Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015 , 6, 231-6	10.3	7
36	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 312-9	21.7	67
35	Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 394-403	3.5	135
34	Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. <i>Investigational New Drugs</i> , 2014 , 32, 569-72	4.3	13
33	Results of the MARS study on the management of antiangiogenics-renovascular safety in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 466-466	2.2	
32	Results of the MARS study on the management of antiangiogenics-renovascular safety in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 394-394	2.2	
31	Results of the MARS study on the management of antiangiogenics-renovascular safety in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5567-5567	2.2	3
30	Results of the MARS study on the management of antiangiogenics-renovascular safety in breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e12504-e12504	2.2	1
29	Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 357-67	3.5	27
28	Treatment of bevacizumab-induced hypertension by amlodipine. <i>Investigational New Drugs</i> , 2012 , 30, 702-7	4.3	47
27	Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2012 , 77, 104-9	5.9	12

26	Saturable absorption of sorafenib in patients with solid tumors: a population model. <i>Investigational New Drugs</i> , 2012 , 30, 1991-2000	4.3	35
25	Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2012 , 30, 2046-9	4.3	78
24	Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. <i>Supportive Care in Cancer</i> , 2012 , 20, 2235-9	3.9	8
23	Increased evidence for use of chemotherapy in pregnancy. <i>Lancet Oncology</i> , 2012 , 13, 852-4	21.7	11
22	Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. <i>American Journal of Obstetrics and Gynecology</i> , 2012 , 207, 514.e1-7	6.4	23
21	Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. <i>Medical Oncology</i> , 2012 , 29, 2793-9	3.7	30
20	Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma. <i>Anti-Cancer Drugs</i> , 2012 , 23, 745-8	2.4	12
19	Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. <i>Anti-Cancer Drugs</i> , 2012 , 23, 739-44	2.4	13
18	First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2557-2557	2.2	2
17	Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2012 , 7, e37563	3.7	196
16	Management of antiangiogenics-renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5067-5067	2.2	
15	Management of antiangiogenics-renovascular safety in breast cancer subgroup and intermediate results of the MARS study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1095-1095	2.2	
14	Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2011 , 47, 515-9	7.5	61
13	Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents. <i>Investigational New Drugs</i> , 2011 , 29, 716-8	4.3	9
12	Cancer du sein associée à la grossesse. <i>Oncologie</i> , 2011 , 13, 645-653	1	4
11	Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. <i>Targeted Oncology</i> , 2011 , 6, 253-8	5	92
10	An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. <i>Oncologist</i> , 2011 , 16, 1325-32	5.7	58
9	Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2010 , 69, 99-101	3.8	32

8	Breast cancer in pregnancy: recommendations of an international consensus meeting. <i>European Journal of Cancer</i> , 2010 , 46, 3158-68	7.5	186
7	Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 1059-63	3.5	15
6	Cisplatin as a cornerstone of modern chemotherapy. <i>Lancet Oncology, The</i> , 2009 , 10, 304	21.7	5
5	Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. <i>Anti-Cancer Drugs</i> , 2009 , 20, 105-8	2.4	10
4	Ectopic pregnancy in a breast cancer patient receiving trastuzumab. <i>Reproductive Toxicology</i> , 2008 , 25, 286-8	3.4	13
3	Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma. <i>Aids</i> , 2008 , 22, 1237-9	3.5	4
2	Use of platinum derivatives during pregnancy. <i>Cancer</i> , 2008 , 113, 3069-74	6.4	97
1	Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms. <i>Gynecologic Oncology</i> , 2007 , 106, 622-5	4.9	2